Form 4: Haemonetics Corp: CFO D'Arecca Reports Stock Transaction

Haemonetics Corp. EVP and Chief Financial Officer James D'Arecca reported a transaction involving the withholding of shares for tax obligations related to vested RSUs.

Summary

• James D'Arecca, EVP and Chief Financial Officer of Haemonetics Corp., engaged in a transaction on May 1, 2026.
• This transaction involved the withholding of 655 shares of common stock to cover tax obligations associated with the vesting of restricted stock units (RSUs).
• The price per share for this withholding was $59.26.
• Following this transaction, D'Arecca beneficially owns 27,637 shares of common stock, which includes unvested RSUs.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it represents a standard administrative transaction related to executive compensation rather than a strategic business development or financial performance indicator.

Positives

• The transaction reflects the settlement of tax obligations related to previously granted equity compensation, indicating the company's compensation structure is functioning as intended.
• The continued ownership of a significant number of shares (27,637) by the CFO suggests ongoing commitment to the company.

Negatives

• The withholding of shares for tax purposes represents a reduction in the number of shares directly held by the executive, although this is a standard practice for equity compensation.

Future Outlook

This filing does not contain forward-looking statements or guidance. It reports a past transaction related to executive compensation.

Industry Context

StockSavvy.ai notes that Form 4 filings are routine disclosures for insider transactions and are standard practice for executives managing their equity compensation and associated tax liabilities. This specific filing pertains to a common event in the healthcare technology sector.

Stakeholder Impact

• Shareholders: The transaction does not directly impact the overall number of outstanding shares or the company's financial performance. It is a standard part of executive compensation.

Key Dates

Keywords

Form 4, SEC Filing, Haemonetics Corp, HAE, James D'Arecca, Chief Financial Officer, Restricted Stock Units, RSUs, Stock Withholding, Tax Obligations, Beneficial Ownership